ADIA Nutrition Inc. Announces Restructuring, Unveiling Two Dynamic Divisions

health news

Winter Park, Florida–(Newsfile Corp. – July 18, 2024) – ADIA Nutrition Inc., (OTC Pink: ADIA) proudly announces a strategic restructuring initiative aimed at enhancing its offerings and expanding its market reach. With a clear vision for growth and innovation, ADIA Nutrition Inc. is excited to introduce its newly formed Medical Division and Supplement Division, each poised to revolutionize their respective sectors.

ADIA Nutrition Inc. Embarks on Transformational Journey, Unveils Two Distinctive Divisions

Under this new structure, ADIA Nutrition Inc. will cater to diverse consumer needs through specialized divisions:

Medical Division:
ADIA Nutrition Inc. takes a bold step forward in healthcare with the launch of its Medical Division. Spearheading this division will be a cutting-edge clinic dedicated to Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis (MS). This pioneering clinic will mark ADIA Nutrition Inc.’s commitment to advancing medical solutions and providing hope to those battling MS.

Supplement Division:
In alignment with its dedication to quality and sustainability, ADIA Nutrition Inc. is proud to present its Supplement Division. This division is dedicated to acquiring and/or investing in supplement companies that uphold the highest standards of manufacturing. ADIA Nutrition Inc. emphasizes a strict criteria focusing on companies utilizing US manufacturing processes and offering organic products. By doing so, the Supplement Division ensures consumers access to premium-quality supplements that align with their wellness goals.

Commenting on the restructuring, Larry Powalisz, CEO of ADIA Nutrition Inc., stated, “Our decision to restructure ADIA Nutrition Inc. reflects our commitment to innovation and fulfilling evolving consumer demands. With the introduction of both our Medical Division and Supplement Division, we are poised to make significant strides in healthcare and wellness. We believe these divisions will not only drive growth for our company but also create positive impacts on the lives of individuals.”

The restructuring marks an exciting chapter in ADIA Nutrition Inc.’s journey, reinforcing its position as a trailblazer in the nutrition industry. The company remains dedicated to pushing boundaries, fostering innovation, and delivering products and services that empower individuals to lead healthier, happier lives.

For media inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division specializing in Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments for Multiple Sclerosis (MS). Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/215956